Legal Opinion

United States ex rel. Polansky v. Pfizer, Inc.

District Court, E.D. New York

Decided November 15, 2012No. 04 Civ. 0704 (BMC)PublishedCited by 7 opinions

1Opinion of the Court

*260 MEMORANDUM DECISION AND ORDER

COGAN, District Judge.

Before the Court is defendant’s motion to dismiss plaintiffs Fifth Amended Complaint in this qui tarn action under the False Claims Act (“FCA”) 31 U.S.C. § 3729 et seq. Plaintiff alleges that Pfizer has engaged in an illegal marketing campaign for its popular statin Lipitor. According to plaintiff, defendant misrepresented the patient populations to whom the drug should be prescribed by encouraging doctors to prescribe Lipitor to lower their patients’ cholesterol even when the patients’ risk factors for cardiac heart disease and their…

2Cases cited3 opinions

  1. United States v. BookerSupreme Court of the United States · 2004
  2. Kordel v. United StatesSupreme Court of the United States · 1948
  3. United States Ex Rel. Carpenter v. Abbott Laboratories, Inc.District Court, D. Massachusetts · 2010

3Cited by7 opinions

  1. United States ex rel. Coyne v. Amgen, Inc.District Court, E.D. New York · 2017
  2. United States ex rel. Polansky v. Pfizer, Inc.Court of Appeals for the Second Circuit · 2016
  3. United States ex rel. Polansky v. Pfizer, Inc.Court of Appeals for the Second Circuit · 2014
  4. United States ex rel. Coyne v. Amgen, Inc.District Court, E.D. New York · 2017
  5. Gardner v. Vanda Pharmaceuticals Inc.District Court, District of Columbia · 2020

2 more not listed; retrieve them via the Exa API.

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API